( DA”) or EuropeanMedicines Agency...)Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO,Health

DA”) or European Medicines Agency
(“EMEA”);
• the safety and efficacy of the Company’s products or product candidates;
• the Company’s assessment of its clinical trials;
• the commencement and completion of clinical trials;
• the Company’s ability to develop, manufacture, license and sell its products or product
candidates;
• the Company’s ability to enter into and successfully execute license and collaborative
agreements, if any;
• the adequacy of the Company’s capital resources and cash flow projections, and the
Company’s ability to obtain sufficient financing to maintain the Company’s planned
operations;
• the adequacy of the Company’s patents and proprietary rights;
• the impact of litigation that has been brought against the Company and its officers and
directors and any proposed settlement of such litigation;
• the Company’s ability to regain compliance with the NASDAQ’s listing qualifications, or
its ability to successfully appeal the NASDAQ delisting; and
• the other risks described under Certain Risks and Uncertainties Related to the
Company’s Business, as contained in the Company’s Annual Report on Form 10-K and
Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a
number of factors that could cause actual results and developments to differ materially. For a
discussion of those risks and uncertainties, please see the Company's Annual Report on Form
10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:
For Genta Incorporated
Tara Spiess/Andrea Romstad
TS Communications Group, LLC
(908) 286-3980
info@genta.c
'"/>




Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery